Congress
$15,001–$50,000
Traded Feb 24, 2025 · disclosed 13 days later
8 different filers disclosed AMGN within 90 days.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Holdings as of Dec 31, 2024 (Q4 2024) · Filed Feb 25, 2025
10 tracked managers disclosed the same change for Q4 2024. From a 13F filed Feb 25, 2025 covering holdings at Dec 31, 2024 — a quarter-end snapshot, not a live trade.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell.
New
Compared with the manager's Q3 2024 13F
95,000
0.36%
Within the filing's reported positions, not the manager's total assets
10
For Q4 2024
Congress
Traded Feb 24, 2025 · disclosed 13 days later
8 different filers disclosed AMGN within 90 days.
Insider selling
Traded Feb 19, 2025 · filed 3 days laterNot reported under a pre-arranged trading plan
Amgen's & Chief Technology Officer sold $2.55M of Amgen shares. The filing does not indicate a pre-arranged trading plan.
David M Reese (EVP & Chief Technology Officer) sold ~$7.68M of Amgen
Automatic saleEvery dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.